Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

144.47 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Jan 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,860
Open 144.47
Bid (Size) 144.79 (1)
Ask (Size) 145.20 (3)
Prev. Close 144.47
Today's Range 144.47 - 144.47
52wk Range 140.68 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 3.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
+0.31%
+0.31%
1 Month
+0.43%
+0.43%
3 Month
-10.60%
-10.60%
6 Month
-3.20%
-3.20%
1 Year
-10.00%
-10.00%

More News

Read More
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy in 2025
Via The Motley Fool
Smart Money Is Betting Big In JNJ Options
Via Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
Via Investor's Business Daily
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
Via Stocktwits
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
A Look At Dividend Kings
Via Talk Markets
Topics ETFs Stocks / Equities
Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
Via The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Via Benzinga
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
Via Investor's Business Daily
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Where to Invest $100,000 in 2025
Via The Motley Fool
Stock Of The Day: Will Johnson & Johnson Take The Market Lower?
Via Benzinga
Neumora Therapeutics Stock Crashes 83% After Depression Drug Flops
Via Investor's Business Daily
Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025
From Johnson & Johnson
Via Business Wire
10 Stock Market Predictions for 2025
Via The Motley Fool
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
Via Benzinga
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
Via Benzinga
Topics Stocks
Exposures US Equities
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Via Benzinga
Exposures Product Safety
5 Unbeatable Stocks I'm Eager to Buy in 2025
Via The Motley Fool
10 Dividend Stocks For Intergenerational Wealth
Via Talk Markets
Topics Stocks / Equities
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.